A Review of Ƙarin Kula Zɓk
Abin sani kawai maganin curative ga myelofibrosis na farko (PMF) shi ne tsinkar sakon cell , duk da haka, ana bada shawarar wannan magani ga marasa lafiya da marasa lafiya. Koda a cikin wannan rukuni, shekarun da wasu yanayi na kiwon lafiya na iya ƙara haɗarin da ke hade da dasawa da muhimmanci wajen sanya shi ƙasa da tsarin farfadowa. Bugu da ƙari, ba dukan mutanen da ke da matsanancin matsanancin matsala na PMF zasu sami mawaki mai dacewa ba wanda zai ba da gudummawa.
An bada shawarar cewa mutanen da ke fama da rashin lafiya na PMF sun sami magani don rage cututtuka da suka shafi cutar.
Zai yiwu likitan ku ya shawarci cewa canji ba shine mafi kyawun zaɓi ba, ko kuma ba mai ba da taimako mai ba da taimako ba, ko kuma ba ku yarda da wasu hanyoyin maganin farko na PMF ba. A al'ada, tambayarka ta gaba zata kasance-menene wasu zaɓuɓɓukan magani suke samuwa? Abin farin cikin, akwai ci gaba da binciken da ke ci gaba da neman ƙarin zaɓuɓɓukan magani. Za mu sake nazarin wasu magunguna nan da nan.
Jak2 Masu hanawa
Ruxolitinib , mai maganin JAK2, shine farkon farfadowa da aka gano don PMF. An yi haɗin kai a cikin jak2 jinsi tare da ci gaban PMF.
Ruxolitinib ya dace da farfadowa ga mutane da waɗannan maye gurbin wanda ba zai iya shafan sashi ba. Abin farin, an samo taimako har ma a cikin mutane ba tare da maye gurbin JAK2 ba.
Akwai bincike na ci gaba da neman neman bunkasa magungunan magungunan (sauran masu hana JAK2) wanda za'a iya amfani dasu a wajen kula da PMF da kuma hada hawan gwiwar rigakafi tare da wasu magunguna.
Momelotinib wani mai hana JAK2 ne wanda ake nazarin magani na PMF. Binciken farko ya nuna cewa kashi 45 cikin 100 na mutanen da suka karbi ragamar mulki sun rage raguwa.
Kimanin rabin mutanen da aka yi nazari sunyi ingantaccen cutar anemia kuma fiye da kashi 50 cikin dari sun iya dakatar da farfadowa na transfusion. Thrombocytopenia (ƙananan ƙidaya platelet) na iya bunkasa kuma zai iya rage tasiri. Momelotinib za a kwatanta shi da ruxolitinib a cikin wani lokaci na 3 binciken don tantance muhimmancinsa wajen magance PMF.
Magunguna marasa lafiya
Pomalidomide wata kwayar cutar ne mai mahimmanci (magunguna da ke canza tsarin rigakafi). Yana da dangantaka da thalidomide da lenalidomide. Gaba ɗaya, ana bada waɗannan magunguna tare da prednisone (magani na steroid).
Thalidomide da lenalidomide an riga an nazarin su a matsayin hanyoyin kulawa a cikin PMF. Ko da yake dukansu suna nuna amfaninsu, yawancin abubuwan da suke da nasaba suna amfani da su. An kafa Pomalidomide a matsayin wani zaɓi mai guba. Wasu marasa lafiya suna samun ci gaba a cikin anemia amma ba a sami sakamako a cikin girman ƙwayar ba. Bisa ga wannan amfani mai iyaka, akwai ci gaba da binciken da ake kallon hada polmalidomide tare da wasu jami'o'in kamar ruxolitinib don kula da PMF.
Epigenetic Drugs
Kwayoyin cututtukan kwayoyi sune magunguna waɗanda ke tasirin maganganun wasu kwayoyin maimakon maimakon canza jiki. Ɗaya daga cikin wadannan magunguna sune wakilan hypomethylating, wanda zai hada da azacitidine da decitabine.
Ana amfani da wadannan magunguna don magance myelodysplastic ciwo . Nazarin da ke kallon muhimmancin azacitidine da decitabine sun kasance a farkon matakan. Sauran magunguna sune masu hana hawan magunguna histone deacetlyase (HDAC) kamar givinostat da panobinostat.
Everolimus
Everolimus magani ne wanda aka kirkira a matsayin mai hana masewa mai cin hanci da immunosuppressant. Shi ne FDA (Abincin da Drug Administration) wanda aka yarda don maganin cututtuka (ƙirjin, ƙwayar ƙwayar ƙwayar ƙwayar cuta, ciwon daji na neuroendocrin, da dai sauransu) da kuma hana ƙin gawar jiki a cikin mutanen da suka karbi suturar kwayoyin (hanta ko koda). Everolimus an dauki baki.
Binciken farko ya nuna cewa zai iya rage alamun bayyanar cututtuka, yalwata girma, anemia, ƙididdigar platinum da ƙididdigar jini.
Imetelstat
An kirkiro Imetelstat a ciwon daji da myelofibrosis. A farkon nazarin, ya haifar da gafara (magunguna da alamomi na PMH) a wasu mutane tare da matsakaici ko kuma PMF.
Idan ba ku amsa maganin farko ba, yin rajista a gwaji na asibiti zai ba ku dama ga magunguna. A halin yanzu, akwai gwaje-gwajen gwaji fiye da 20 na gwajin maganin zafin jiki don mutanen da ke da myelofibrosis. Zaka iya tattauna wannan zabin tare da likita.
> Sources:
> Cervantes F. Yaya zan bi myelofibrosis na farko. Jinin jini. 2014; 124: 2635-2642.
> Geyer HL da Mesa RA. Far ga mophofafuwar neoplasms: a yaushe, wane wakili, kuma ta yaya? Jinin jini. 2014; 124: 3529-3537.